Joseph Turner
Director/Board Member bij Swarthmore College
Vermogen: 42 732 $ op 31-03-2024
Profiel
Joseph L.
Turner is an Independent Director at Rainier Therapeutics, Inc. and a Member-Managers Board at Swarthmore College.
He previously held positions as a Director at QLT, Inc., Allos Therapeutics, Inc., Corcept Therapeutics, Inc., Sophiris Bio, Inc., Alexza Pharmaceuticals, Inc., Kythera Biopharmaceuticals LLC, SGX Pharmaceuticals, Inc., TOLMAR Therapeutics, Inc., and Centaur Pharmaceuticals, Inc. He was also a Director at NovaCardia, Inc., Sequel Pharmaceuticals, Inc., Nora Therapeutics, Inc., Linda Crnic Institute for Down Syndrome, and Viridian Therapeutics, Inc. Turner's education includes an undergraduate degree from Swarthmore College, a graduate degree from The University of Colorado, and an MBA from The University of North Carolina at Charlotte.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 03-04-2023 | 4 312 ( 0.00% ) | 42 732 $ | 31-03-2024 |
Actieve functies van Joseph Turner
| Bedrijven | Functie | Begin |
|---|---|---|
| Swarthmore College | Director/Board Member | 17-12-2013 |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Director/Board Member | - |
Eerdere bekende functies van Joseph Turner
| Bedrijven | Functie | Einde |
|---|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Director/Board Member | 31-05-2023 |
| ALEXZA PHARMACEUTICALS, INC. | Director/Board Member | 21-06-2016 |
| SOPHIRIS BIO | Director/Board Member | 27-05-2016 |
| CORCEPT THERAPEUTICS INCORPORATED | Director/Board Member | 01-05-2016 |
| KYTHERA BIOPHARMACEUTICALS INC | Director/Board Member | 01-10-2015 |
Opleiding van Joseph Turner
| Swarthmore College | Undergraduate Degree |
| The University of Colorado | Graduate Degree |
| The University of North Carolina at Charlotte | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CORCEPT THERAPEUTICS INCORPORATED | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| ARCUTIS BIOTHERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 14 |
|---|---|
| Cortech, Inc. | Health Technology |
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
| Centaur Pharmaceuticals, Inc. | Health Technology |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Sophiris Bio, Inc.
 Sophiris Bio, Inc. Pharmaceuticals: MajorHealth Technology Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. | Health Technology |
Gilead Colorado, Inc.
 Gilead Colorado, Inc. Pharmaceuticals: MajorHealth Technology Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO. | Health Technology |
Alexza Pharmaceuticals, Inc.
 Alexza Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexza Pharmaceuticals, Inc. is a pharmaceutical company. It focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are AZ-002 and AZ-007. The company was founded by Alejandro C. Zaffaroni in 2000 and is headquartered in Mountain View, CA. | Health Technology |
NovaCardia, Inc.
 NovaCardia, Inc. Pharmaceuticals: MajorHealth Technology NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA. | Health Technology |
Kythera Biopharmaceuticals LLC
 Kythera Biopharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Kythera Biopharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The company was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David, and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Westlake, CA. | Health Technology |
SGX Pharmaceuticals, Inc.
 SGX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA. | Health Technology |
TOLMAR Therapeutics, Inc.
 TOLMAR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TOLMAR Therapeutics, Inc. provides healthcare services. The company's products include Eligard, a prostate cancer treatment, Aczone, a dermatology product for the treatment of acne, and Atrigel, a drug delivery system. Its drug delivery systems deliver medicines such as proteins and antibiotics. The company also makes Orajel and Cepacol mouth sore medicines. It is headquartered in Fort Collins, CO. | Health Technology |
Sequel Pharmaceuticals, Inc.
 Sequel Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Sequel Pharmaceuticals, Inc. engaged in the development of cardiovascular drug. The company was founded in 2007 and was headquartered in San Diego, CA. | Retail Trade |
Nora Therapeutics, Inc.
 Nora Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nora Therapeutics, Inc. develops therapeutics to address clinical unmet needs in reproductive medicine. Its's lead product NT100, seeks to improve pregnancy outcomes in women undergoing in vitro fertilization or who have suffered recurrent spontaneous miscarriages. The company was founded by Darryl L. Carter and Chris B. McClain in 2007 and is headquartered in Palo Alto, CA. | Health Technology |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
